Bibliography
- Schteingart DE. Cushing's syndrome. Chapter 75. In: Becker KL, editor. Principles and Practice of Endocrinology and Metabolism. 3rd edition. Lippincott Williams and Wilkins publ. 530 Walnut St, Philadelphia, PA, 19106, USA; 2001. p. 723-38
- Pivonello R, DeMartino MC, Cappabianca P, The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated with surgery. J Clin Endocrinol Metab 2009;94(1):223-30
- Ambrosi B, Dall'Asta C, Cannavo S, Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151:173-8
- Pecori Girardi F, Scaroni C, Arvat E, Effect of protracted treatment with rosiglitazone, a PPAR-gamma agonist, in patients with Cushing's disease. Clin Endocrinol 2006;64:219-24
- Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's Disease. J Clin Endocrinol Metab 2005;90:1340-6
- Mullan KR, Leslie H, McCance DR, The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol 2006;64:519-22
- Schteingart DE. Drugs in the medical treatment of Cushing's syndrome. Expert Opinion on Emerging Drugs 2009;14(4):661-71
- Fleseriu M, Biller BMK, Findling JW, Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with refractory Cushing syndrome: results from the Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome (SEISMIC). Presented at: The Endocrine Society 93rd Annual Meeting & Expo; 4 – 7 June 2011; Boston
- Colao A, Petersenn S, Newell-Prince J, Pasireotide (SOM230) Demonstrates Efficacy in Patients With Cushing's Disease: Results From a Large, Randomized-Dose, Double-Blind, Phase III Study. Presented at: The Endocrine Society 93rd Annual Meeting & Expo; 4 – 7 June 2011; Boston
- Castinetti F, Fassnacht M, Johanssen S, Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009;160:1003-10
- Belanoff JK, Rothschild AJ, Cassidy F, An open-label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002;52(5):386-92
- de Bruin C, Pereira AM, Feelders RA, Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009;94:1118-24
- De Herder WW, Lamberts SWJ. Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Editorial. Postgrad Med J 2005;352:2457-8
- Boscaro M, Ludlam WH, Atkinson B, Treatment of pituitary-ACTH dependent Cushing's disease with a multireceptor ligand somatostatin analog pasireotide (SOM 230). A multicenter, phase II trial. J Clin Endocrinol Metab 2009;94:115-22
- Castinetti F, Morange I, Jaquet P, Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008;158:91-9
- Jeffcoate WJ, Rees LH, Tomlin S, Metyrapone in long-term management of Cushing's disease. Br Med J 1977;2(6081):215-17
- Schteingart DE, Tsao HS, Taylor CI, Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980;92:613-19
- Schulte HM, Benker G, Reinwein D, Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990;70:1426-30
- Greening JE, Brain CE, Perry LA, Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 2005;64:140-3